Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term CTAP101 in CKD with SHPT
NCT02282813Phase 3Completed
- Sponsor
- OPKO Health
- Start
- Apr 2013
- Primary completion
- May 2015
- Modality
- Orthosteric Ligands
01
Overview
Phase 3, randomised, open-label trial of calcifediol in secondary hyperparathyroidism (SHPT) and Vitamin D deficiency (VDD) (4 arms), sponsored by OPKO Health. Primary endpoint: Number of Participants in the Intent to Treat Population With a Mean Reduction in Plasma Intact Parathyroid Hormone (iPTH) of >/= 30% From Baseline Values at End of Treatment (EOT) at 6 months. Started Apr 2013; status: completed.
02
Drugs
calcifediol
03
Conditions
secondary hyperparathyroidism (SHPT)Vitamin D deficiency (VDD)
Beyond the preview
Go deeper on NCT02282813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02282813.